|
A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients |
ofatumumab |
COMB157G2102 |
NCT03560739 |
Multiple Sclerosis |
Phase 2 |
|
|
|
|
|
February 2023 |